Navigation Links
Previous Claims of siRNA Therapeutic Effects Called into Question by Report in 'Human Gene Therapy'
Date:9/2/2008

NEW ROCHELLE, N.Y., Sept. 2 /PRNewswire/ -- The many recent reports documenting the therapeutic efficacy of short interfering RNAs (siRNAs) in animal models of human disease may actually be describing non-specific therapeutic effects related to the ability of siRNA to activate an immune response, according to a paper in the September 2008 issue (Volume 19, Number 9) of 'Human Gene Therapy,' a peer-reviewed journal published by Mary Ann Liebert, Inc. The paper, which was published "instant online," is available free online at http://www.liebertpub.com/hum

Marjorie Robbins, Adam Judge, Ellen Ambegia, Catherine Choi, Ed Yaworski, Lorne Palmer, Kevin McClintock, and Ian MacLachaln of Protiva Biotherapeutics (Burnaby, BC Canada), in a paper entitled, "Misinterpreting the Therapeutic Effects of siRNA Caused by Immune Stimulation," emphasize the need for researchers to design siRNA studies that incorporate suitable controls to differentiate the disease-modulating effect of an siRNA from its ability to stimulate an innate immune response.

siRNAs have been highly touted for their ability to target very specifically and selectively the disease-causing factors in a range of disorders, from viral infections to tumors and inflammatory and immunologic processes. However, siRNA also has the potential to activate innate immunity and the production of interferons, which can in turn bring about therapeutic effects in a range of disease models.

The authors of this paper contend that, "Surprisingly few of the reported studies have adequately tested, or controlled, for the potential effects of siRNA-mediated immune stimulation."

In the current study, use of a commonly used control siRNA sequence called GFP siRNA, which has only a minimal capacity to activate the immune system, clearly showed the striking difference between the immunostimulatory potential of GFP siRNA and of some other siRNAs. Using a mouse model of influenza, the authors demonstrated that the anti-viral activity of siRNA is mainly due to non-specific stimulation of the immune system rather than to a targeted attack on the disease-causing virus.

"siRNA holds tremendous potential as a research tool, however its clinical development is still in its infancy. The study by Robbins et al. points out a very important issue regarding non-specific effects that should be considered when designing and evaluating siRNA strategies," says James M. Wilson, MD, PhD, Editor-in-Chief, and Head of the Gene Therapy Program, Division of Medical Genetics, University of Pennsylvania School of Medicine, in Philadelphia.

'Human Gene Therapy,' the Official Journal of the European Society of Gene and Cell Therapy (http://www.esgct.org), the British Society for Gene Therapy (http://www.bsgt.org), and the French Society of Cell and Gene Therapy (http://www.sftcg.fr), is an authoritative peer-reviewed journal published monthly in print and online that presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Tables of contents and a free sample issue may be viewed online at http://www.liebertpub.com

Mary Ann Liebert, Inc (http://www.liebertpub.com) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including 'Tissue Engineering', 'Stem Cells and Development', and 'Cloning and Stem Cells'. Its biotechnology trade magazine, 'Genetic Engineering & Biotechnology News (GEN)', was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 60 journals, books, and newsmagazines is available at http://www.liebertpub.com

Contact: Vicki Cohn, Mary Ann Liebert, Inc, (914) 740-2100, ext. 2156, vcohn@liebertpub.com


'/>"/>
SOURCE Mary Ann Liebert, Inc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
2. Risks Associated With Face Transplants May Be Lower Than Previously Thought, ASPS Journal Review Suggests
3. Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
4. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
5. CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
6. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
7. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
8. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
9. Results Published in the Journal Cancer Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma
10. Pressure Cycling Technology (PCT) Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer, Stroke, and IVF Studies
11. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Feb. 9, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... editing, today reported its fourth quarter and full ... in vivo therapeutic genome editing," said Edward ... zinc finger nuclease (ZFN) technology leads the therapeutic ... core competencies necessary to move our ground-breaking genome ...
(Date:2/9/2016)... HAMILTON, Bermuda, Feb. 9, 2016  Axovant Sciences ... focused on the treatment of dementia, today announced ... address cognitive, behavioral and functional aspects of Lewy ... people in the U.S. Two out of the ... is expected to start later this quarter. In ...
(Date:2/9/2016)... The new report "Global Diagnostic Ultrasound Devices Market Assessment & Forecast: ... global diagnostic ultrasound devices market was valued at US$ 5,381.1 million ... 2019 at a CAGR of 6.8% from 2015 to 2019. ... analyzed for six geographies of North America , ... Latin America , Middle-East and ...
Breaking Medicine Technology:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... Boston Store, Carson’s, Elder-Beerman, Herberger’s and Younkers department stores, announced it has raised ... of Wisconsin Cancer Center, Holden Comprehensive Cancer Center at the University of Iowa, ...
(Date:2/9/2016)... San Diego, California (PRWEB) , ... February 09, ... ... the launch of their new nationwide service to expand access to affordable ... over 30 million hard of hearing individuals in the United States. , “For ...
(Date:2/9/2016)... Florida (PRWEB) , ... February 09, 2016 , ... ... cold therapy products, announced today the introduction of the newly designed, innovative shoulder ... comfort and better cold therapy coverage for the injured arm and shoulder to ...
(Date:2/9/2016)... ... 09, 2016 , ... United Methodist Communications collaborated with Chocolate ... animated video designed to prevent the next widespread Ebola outbreak from ... being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire and other African ...
(Date:2/9/2016)... ... February 09, 2016 , ... i2i Systems, an early innovator and ... data vendors in the latest KLAS report, Population Health Management 2015: How Far Can ... market for population health management (PHM). The latest KLAS Report, leveraging over 200 ...
Breaking Medicine News(10 mins):